These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2449 related items for PubMed ID: 18519975

  • 1. Molecular control of lymphatic metastasis.
    Achen MG, Stacker SA.
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [Abstract] [Full Text] [Related]

  • 2. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
    Feng Y, Wang W, Hu J, Ma J, Zhang Y, Zhang J.
    Anat Rec (Hoboken); 2010 May; 293(5):802-12. PubMed ID: 20225197
    [Abstract] [Full Text] [Related]

  • 3. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B, Ma J, Wang X, Su F, Li X, Yang S, Ma W, Zhang Y.
    Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
    [Abstract] [Full Text] [Related]

  • 4. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
    Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO.
    Cancer Res; 2005 Nov 01; 65(21):9789-98. PubMed ID: 16267000
    [Abstract] [Full Text] [Related]

  • 5. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED.
    Prostate; 2013 May 01; 73(6):563-72. PubMed ID: 23038639
    [Abstract] [Full Text] [Related]

  • 6. Tumor-induced lymphangiogenesis: a target for cancer therapy?
    Thiele W, Sleeman JP.
    J Biotechnol; 2006 Jun 25; 124(1):224-41. PubMed ID: 16497404
    [Abstract] [Full Text] [Related]

  • 7. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [Abstract] [Full Text] [Related]

  • 8. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.
    Cancer Res; 2008 Jun 15; 68(12):4754-62. PubMed ID: 18559522
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.
    Tobler NE, Detmar M.
    J Leukoc Biol; 2006 Oct 15; 80(4):691-6. PubMed ID: 16793912
    [Abstract] [Full Text] [Related]

  • 13. Pathways targeting tumor lymphangiogenesis.
    Wissmann C, Detmar M.
    Clin Cancer Res; 2006 Dec 01; 12(23):6865-8. PubMed ID: 17145802
    [Abstract] [Full Text] [Related]

  • 14. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
    Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S.
    Clin Cancer Res; 2000 Jun 01; 6(6):2431-9. PubMed ID: 10873096
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tumor lymphangiogenesis and melanoma metastasis.
    Rinderknecht M, Detmar M.
    J Cell Physiol; 2008 Aug 01; 216(2):347-54. PubMed ID: 18481261
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node.
    Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, Vassy R, Czernichow S, Letoumelin P, Breau JL, Bernaudin JF, Kraemer M.
    Lung Cancer; 2007 Nov 01; 58(2):205-13. PubMed ID: 17686546
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M.
    Cancer Res; 2006 Mar 01; 66(5):2650-7. PubMed ID: 16510584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 123.